These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26517111)

  • 1. Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.
    Casado JL; Bañón S
    Expert Rev Clin Pharmacol; 2015; 8(6):709-18. PubMed ID: 26517111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.
    Rizzardo S; Lanzafame M; Lattuada E; Bragantini D; Nicolè S; Calza L; Tacconelli E
    Int J STD AIDS; 2019 Apr; 30(5):467-471. PubMed ID: 30999834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine.
    de Lazzari E; Lonca M; Rojas J; Gonzalez-Cordon A; Blanch J; Inciarte A; Tricas A; Rodriguez A; Martinez-Rebollar M; Laguno M; Mallolas J; Sanchez-Palomino S; Plana M; Blanco JL; Martinez E
    AIDS; 2019 Oct; 33(12):1891-1896. PubMed ID: 31335805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
    Taburet AM; Sauvageon H; Grinsztejn B; Assuied A; Veloso V; Pilotto JH; De Castro N; Grondin C; Fagard C; Molina JM
    Clin Infect Dis; 2015 Oct; 61(8):1328-35. PubMed ID: 26105170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection.
    Deeks ED
    Drugs; 2017 Oct; 77(16):1789-1795. PubMed ID: 29071467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single- and Multiple-Dose Pharmacokinetics of Once-Daily Formulations of Raltegravir.
    Krishna R; Rizk ML; Larson P; Schulz V; Kesisoglou F; Pop R
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):196-206. PubMed ID: 28419778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
    Bollen P; Reiss P; Schapiro J; Burger D
    Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
    Jansen A; Colbers EP; van der Ven AJ; Richter C; Rockstroh JK; Wasmuth JC; van Luin M; Burger DM
    HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
    Rossetti B; Meini G; Bianco C; Lamonica S; Mondi A; Belmonti S; Fanti I; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
    J Clin Virol; 2017 Jun; 91():18-24. PubMed ID: 28395180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five years' real-life experience with raltegravir in a large HIV centre.
    van Halsema C; Whitfield T; Lin N; Ashton K; Torkington A; Ustianowski A
    Int J STD AIDS; 2016 Apr; 27(5):387-93. PubMed ID: 25931236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
    Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
    Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV.
    Bukkems VE; Post TM; Colbers AP; Burger DM; Svensson EM
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):161-172. PubMed ID: 33369217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.
    Calcagno A; Montrucchio C; Capetti A; Guaraldi G; Cenderello G; Calza L; Lanzafame M; Marinaro L; Tettoni MC; Trentini L; D'Avolio A; Di Perri G; Bonora S
    Curr HIV Res; 2016; 14(1):54-60. PubMed ID: 26415700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.
    Galli L; Poli A; Muccini C; Galizzi N; Danise A; Spagnuolo V; Gianotti N; Carini E; Lazzarin A; Castagna A
    Infect Dis (Lond); 2018 Mar; 50(3):220-222. PubMed ID: 28891371
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
    Nachman S; Alvero C; Teppler H; Homony B; Rodgers AJ; Graham BL; Fenton T; Frenkel LM; Browning RS; Hazra R; Wiznia AA;
    Lancet HIV; 2018 Dec; 5(12):e715-e722. PubMed ID: 30527329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.
    Blonk MI; Colbers AP; Hidalgo-Tenorio C; Kabeya K; Weizsäcker K; Haberl AE; Moltó J; Hawkins DA; van der Ende ME; Gingelmaier A; Taylor GP; Ivanovic J; Giaquinto C; Burger DM; ;
    Clin Infect Dis; 2015 Sep; 61(5):809-16. PubMed ID: 25944344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.